Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

NEWPORT BEACH, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- , LLC (“ROTH”), announced today the addition of five ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from Market Perform to Outperform. As of December 23, 2024, the average one ...

Quest Diagnostics (NYSE:DGX – Get Free Report) was upgraded by Leerink Partners from a “market perform” rating to an ...

Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and ...

Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $14.53 per share for ...

On Monday, Leerink Partners upgraded Align Technology (NASDAQ:ALGN) shares from Market Perform to Outperform and increased the price target to $280 from $235. The firm's analysts cited an improved ...